|
Aurobindo Pharma, a second largest Indian pharma company with revenues of Rs. 31,700 crore plus, has posted single digit growth in revenues as well as profits during the second quarter ended September 2025. Its consolidated revenue increased by 6.3 per cent to Rs. 8,286 crore from Rs. 7,796 crore in the corresponding period of last year. Its operating profit increased by 5.6 per cent to Rs. 1,274 crore from Rs. 1,207 crore and net profit moved up by 3.8 per cent to Rs. 848 crore from Rs. 817 crore. EPS worked out to Rs. 14.61 as compared to Rs. 14 in the last period.
Aurobindo’s US formulation sales increased only by 3.1 per cent to Rs. 3,638 crore during the September quarter as compared to Rs. 3,530 crore and contributed 43.9 per cent to its total revenues. Its European sales, however, improved smartly by 17.8 per cent to Rs. 2,480 crore from Rs. 2,105 crore. Sales in growth market moved up by 8.7 per cent to Rs. 882 crore and that of ARV sales up by 68.7 per cent to Rs. 325 crore. International sales worked out to 91 per cent and its domestic sales contributed 9 per cent to total sales. API sales declined by 16.9 per cent to Rs. 961 crore from Rs. 1,156 crore.
K Nithyananda Reddy, vice-chairman and managing director, said: “Q2 has been another steady quarter for Aurobindo, demonstrating the resilience of our base business and the depth of our product portfolio. We continue to see healthy demand across key markets, with our US and Europe businesses performing in line with expectations. The balance between growth and profitability remains central to our execution. With the momentum we’ve built and all strategic initiatives progressing as planned, we are confident of meeting our annual guidance and sustaining long-term value creation.”
The company’s R&D expenditure touched to Rs. 414 crore during the second quarter ended September 2025, primarily towards biosimilars and specialty products development. As at the of end of September 2025, on a cumulative basis, the company has filed 876 ANDAs with US FDA and received 711 final approvals and 31 tentative approvals. It has launched 6 products during the quarter. It also filed one DMFs and submitted 220 formulation dossiers. Three biosimilar products, including trastuzumab biosimilar, approved by European Commission, and four biosimilar products including two monoclonal antibodies – bevacizumab and trastuzumab biosimilars, by MHRA, UK.
For the first half ended September 2025, Aurobindo’s consolidated revenue increased by 5.1 per cent to Rs. 16,154 crore from Rs. 15,363 crore in the similar period of last year. However, its net profit declined by 3.6 per cent to Rs. 1,672 crore from Rs. 1,735 crore.
|